Medicare Part D is an incredibly important and successful program that provides seniors and persons with disabilities with access to affordable prescription drug coverage. While recent surveys indicating about 90 percent of beneficiaries are satisfied with their Part D coverage, you may not know about all the ways Medicare provides value to beneficiaries.
Most Recent Posts
For the biopharmaceutical industry, patient well-being is at the center of everything we do. In keeping patients at the forefront, we are doing all that we can to help people live longer, healthier lives. This week, we highlighted just a few ways we are working to translate that commitment into tangible outcomes.
Many people likely don’t realize that the human papillomavirus, or HPV, is one of the most prevalent sexually transmitted diseases in the United States. This means 79 million Americans, both men and women, currently carry the virus, which in some cases can lead to cervical cancer.
While the Affordable Care Act (ACA) expanded access to health insurance coverage for millions, a new study from the Harvard T.H. Chan School of Public Health reveals that insurers may be discriminating against patients through the drug benefit design of Essential Health Benefit plans.
Since the publication of this post, the Alzheimer’s Association released a new report, “Changing the Trajectory of Alzheimer's Disease: How a Treatment by 2025 Saves Lives and Dollars,” that examines the potential lives saved and economic impact if a treatment is discovered that delays the onset of Alzheimer’s disease by 2025. Key findings of the report include:
As someone who grew up around the biopharmaceutical industry and knows firsthand the impact that it has on local communities, I’m frequently reminded of our members’ far-reaching impact in my role as liaison between PhRMA and the Pharmaceutical Industry Labor-Management Association.
Although we are not even a month into 2015, the U.S. trade agenda has already taken center stage and this coming week will prove to be no different. Less than 24 hours after returning from his trip to India with President Obama to further advance our trading relationship there, United States Trade Representative Michael Froman testified before both the U.S.
PhRMA supports Secretary Burwell’s goal of advancing affordable, high quality and patient centered health care, and today’s announcement represents an important step forward.
Now that 2015 is underway, it’s time to put our guiding principles into action. Our goal is to build on successes from 2014 to help patients live long, healthy lives. This week we started to put those plans into motion. We hope you’ll take an active interest in what we’re working on this year and share your thoughts with us.
Developing innovative, lifesaving medicines for patients is the sole focus of the biopharmaceutical industry. PhRMA member companies invested more than $50 billion in research and development (R&D) in 2013 and over half a trillion dollars since 2000. This represents the vast majority of all biopharmaceutical R&D spending – both private and government – in the United States.
When President Obama held his end-of-year press conference last month, he struck a clear and upbeat tone: “A new future is ready to be written. We've set the stage for this American moment. And I'm going to spend every minute of my last two years making sure that we seize it.”
In 2014, the FDA’s Center for Drug Evaluation and Research (CDER) approved a record 41 new medicines, making it a particularly strong year of innovation for America’s biopharmaceutical companies. This continues a trend in recent years towards a higher annual number of new medicines.
Why are medicines expensive? As we’ve noted previously, it’s a good question that deserves a thorough, balanced discussion.
By all accounts, 2014 presented a number of opportunities and challenges that highlighted just how important it is to keep the patient at the center of our ongoing efforts. It’s a notion that extends well beyond our industry, and should be a guiding principle as we head into 2015.
In 1989, while the world watched the Berlin Wall fall and history opened a new chapter, researchers in government and private labs half a world away were documenting a different beginning: the identification of the hepatitis C virus.
For the past 25 years, the resulting disease has remained largely incurable and often fatal for the world’s 170 million patients with the disease. Until now.